TITLE

Basic Science - Diabetes

PUB. DATE
March 2009
SOURCE
Current Medical Literature: Diabetes;2009, Vol. 26 Issue 1, p30
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
The article presents abstracts of medical research on diabetes including "Role of Central Nervous System Glucagon-like Peptide-1 Receptors in Enteric Glucose Sensing," "Brain Glucagon-like Peptide-1 Regulates Arterial Blood Flow, Heart Rate and Insulin Sensitivity" and "Changes in Transferrin Are Related to Changes in Insulin Resistance."
ACCESSION #
42838848

 

Related Articles

  • Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities. Mossello, Enrico; Ballini, Elena; Boncinelli, Marta; Monami, Matteo; Lonetto, Giuseppe; Mello, Anna Maria; Tarantini, Francesca; Baldasseroni, Samuele; Mannucci, Edoardo; Marchionni, Niccolò // Experimental Diabetes Research;2011, Special section p1 

    Metabolic and neurodegenerative disorders have a growing prevalence in Western countries. Available epidemiologic and neurobiological evidences support the existence of a pathophysiological link between these conditions. Glucagon-like peptide 1 (GLP-1), whose activity is reduced in insulin...

  • Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes. Hernández, Cristina; Bogdanov, Patricia; Corraliza, Lidia; García-Ramírez, Marta; Solà-Adell, Cristina; Arranz, José A.; Arroba, Ana I.; Valverde, Angela M.; Simó, Rafael // Diabetes;Jan2016, Vol. 65 Issue 1, p172 

    Retinal neurodegeneration is an early event in the pathogenesis of diabetic retinopathy (DR). Since glucagon-like peptide 1 (GLP-1) exerts neuroprotective effects in the central nervous system and the retina is ontogenically a brain-derived tissue, the aims of the current study were as follows:...

  • Direct Effect of GLP-1 on Endothelial Function in Nondiabetic Humans. Basu, Ananda; Charkoudian, Nisha; Schrage, William; Lakshmi, Somaraju; Giesler, Paula; Johnson, Christopher P.; Basu, Rita; Joyner, Michael J. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA369 

    Prior data have hinted at cardiovascular beneficial effects of GLP-1 in humans. However, the extent to which these effects were due to GLP-1 per se rather than from alterations in hormone and glucose levels remains unknown. In order to evaluate the effects of GLP-1 per se on endothelial...

  • Development of new incretin drugs: Promising therapies. Kaur, K.; Gautam, C. S. // Indian Journal of Pharmacology;Apr2006, Vol. 38 Issue 2, p100 

    New agents are being added to the armamentarium of drugs used for the treatment of diabetes mellitus. Today, extensive research is being conducted on incretin hormones. Important among them are, Glucagon like peptide-1 (GLP-1) and Glucose dependent insulinotropic peptide (GIP). The...

  • GLP-1.  // Diabetologia;Aug2000 Supplement 1, Vol. 43, pA30 

    The article presents abstracts of studies of glucagon-like peptide (GLP)-1, reported at the 36th annual meeting of the European Association for the Study of Diabetes in Jerusalem, from September 17 to 21, 2000. They include "Expression of the glucagon-like peptide-1 receptor and glucokinase in...

  • GLP-1 Analogues I.  // Diabetologia;Aug2000 Supplement 1, Vol. 43, pA144 

    The article presents abstracts of studies of glucagon-like peptide (GLP)-1 analogues, reported at the 36th annual meeting of the European Association for the Study of Diabetes in Jerusalem, from September 17 to 21, 2000. They include "Subcutaneous exendin-4 lowers both post-prandial and fasting...

  • GLP-1 Analogues II.  // Diabetologia;Aug2000 Supplement 1, Vol. 43, pA146 

    The article presents abstracts of studies of glucagon-like peptide (GLP)-1 analogues, reported at the 36th annual meeting of the European Association for the Study of Diabetes in Jerusalem, from September 17 to 21, 2000. They include "Decreased fasting GLP-1 levels in type-2 diabetes,"...

  • Erratum to: Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Aoki, Kazutaka; Kamiyama, Hiroshi; Yoshimura, Kouichiro; Shibuya, Makoto; Masuda, Kiyomi; Terauchi, Yasuo // Acta Diabetologica;Jun2012, Vol. 49 Issue 3, p231 

    A correction to the article "Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin" that was published in the November 1, 2011 issue is presented.

  • European drugs agency clashes with scientists over GLP-1 drugs. Cohen, Deborah // BMJ: British Medical Journal;8/3/2013, Vol. 347 Issue 7919, p2 

    The article informs that the European Medicines Agency has states that the agency had no new concerns about the available clinical trail data of drugs including incretin mimetics and dipeptidyl peptidase-4 (DPP-4) inhibitors.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics